Michael Cherny
Stock Analyst at B of A Securities
(4.15)
# 342
Out of 5,182 analysts
121
Total ratings
56.84%
Success rate
12.41%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Buy | $1,040 → $1,000 | $828.32 | +20.73% | 16 | Apr 6, 2026 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $18 → $25 | $29.39 | -14.94% | 12 | Mar 16, 2026 | |
| TDOC Teladoc Health | Maintains: Market Perform | $8.5 → $5.5 | $5.85 | -5.98% | 2 | Feb 26, 2026 | |
| HSIC Henry Schein | Maintains: Market Perform | $75 → $87 | $77.20 | +12.69% | 3 | Feb 24, 2026 | |
| ACH Accendra Health | Maintains: Market Perform | $3 → $2.75 | $3.42 | -19.59% | 1 | Feb 20, 2026 | |
| XRAY DENTSPLY SIRONA | Upgrades: Buy | $13 → $17 | $11.96 | +42.14% | 9 | Feb 19, 2026 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $421.37 | +15.10% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $78.36 | +21.24% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $45.23 | +6.12% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $6.24 | +108.33% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $203 → $210 | $196.63 | +6.80% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $188 → $186 | $202.34 | -8.08% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $28 | $18.41 | +52.09% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $3 | $1.47 | +104.08% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $23 | $26.77 | -14.08% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $24.66 | +264.96% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $184.70 | +51.60% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $163.84 | +51.37% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $103.21 | +147.07% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $310.16 | -11.34% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $263.43 | -1.30% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.28 | +250.88% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $1.17 | +4,387.18% | 2 | Jan 5, 2022 |
McKesson
Apr 6, 2026
Maintains: Buy
Price Target: $1,040 → $1,000
Current: $828.32
Upside: +20.73%
Hims & Hers Health
Mar 16, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $29.39
Upside: -14.94%
Teladoc Health
Feb 26, 2026
Maintains: Market Perform
Price Target: $8.5 → $5.5
Current: $5.85
Upside: -5.98%
Henry Schein
Feb 24, 2026
Maintains: Market Perform
Price Target: $75 → $87
Current: $77.20
Upside: +12.69%
Accendra Health
Feb 20, 2026
Maintains: Market Perform
Price Target: $3 → $2.75
Current: $3.42
Upside: -19.59%
DENTSPLY SIRONA
Feb 19, 2026
Upgrades: Buy
Price Target: $13 → $17
Current: $11.96
Upside: +42.14%
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $421.37
Upside: +15.10%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $78.36
Upside: +21.24%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $45.23
Upside: +6.12%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $6.24
Upside: +108.33%
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $196.63
Upside: +6.80%
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $202.34
Upside: -8.08%
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $18.41
Upside: +52.09%
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.47
Upside: +104.08%
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $26.77
Upside: -14.08%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $24.66
Upside: +264.96%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $184.70
Upside: +51.60%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $163.84
Upside: +51.37%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $103.21
Upside: +147.07%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $310.16
Upside: -11.34%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $263.43
Upside: -1.30%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.28
Upside: +250.88%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $1.17
Upside: +4,387.18%